Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas

被引:23
作者
Maleno, I
Nevot, MAL
Seliger, B
Garrido, F
机构
[1] Hosp Univ Virgen Nieves, Dept Anal Clin, Granada 18014, Spain
[2] Johannes Gutenberg Univ Mainz, Dept Internal Med, D-6500 Mainz, Germany
关键词
RCC; LOH; HLA; escape; tumor immunity;
D O I
10.1002/ijc.20000
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HLA class 1 loss or downregulation is a widespread mechanism used by tumor cells to avoid tumor recognition by cytotoxic T lymphocytes favoring tumor immune escape. Multiple molecular mechanisms are responsible for these altered HLA class 1 tumor phenotypes. It has been described in different epithelial tumors that loss of heterozygosity (LOH) at chromosome region 6p21.3 is a frequent mechanism that leads to HLA haplotype loss, ranging between 40 and 50%, depending on the tumor entity analyzed. Here we have tested the frequency of LOH at 6p21 chromosome region in Renal Cell Carcinomas (RCC) of the clear cell and chromophobe subtype. A low frequency of HLA haplotype loss (6.6%) was found in clear cell RCC. These data significantly differ from those reported in other epithelial tumors. In contrast, in RCC of chromophobe subtype this frequency was 10 times higher (3 out of 5 cases analyzed). These results indicate that LOH at 6p21.3 is not a frequent mechanism that leads to HLA class 1 abnormalities in clear cell RCC. In addition, the chromophobe RCC subtypes differ not only in histopathological criteria but also in the frequency of LOH-mediating HLA class 1 alterations. These results might help to understand the significantly different biological behavior of both RCC subtypes. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:636 / 638
页数:3
相关论文
共 35 条
[1]   Immunotherapy for renal cell carcinoma [J].
Bleumer, I ;
Oosterwijk, E ;
De Mulder, P ;
Mulders, PFA .
EUROPEAN UROLOGY, 2003, 44 (01) :65-75
[2]   TISSUE TYPING THE HLA-A LOCUS FROM GENOMIC DNA BY SEQUENCE-SPECIFIC PCR - COMPARISON OF HLA GENOTYPE AND SURFACE EXPRESSION ON COLORECTAL TUMOR-CELL LINES [J].
BROWNING, MJ ;
KRAUSA, P ;
ROWAN, A ;
BICKNELL, DC ;
BODMER, JG ;
BODMER, WF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (07) :2842-2845
[3]  
Bukowski RM, 1999, ONCOLOGY-NY, V13, P801
[4]  
Contractor H, 1997, J PATHOL, V181, P136, DOI 10.1002/(SICI)1096-9896(199702)181:2<136::AID-PATH766>3.0.CO
[5]  
2-2
[6]   Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression [J].
Feenstra, M ;
Verdaasdonk, M ;
van der Zwan, AW ;
de Weger, R ;
Slootweg, P ;
Tilanus, M .
LABORATORY INVESTIGATION, 2000, 80 (03) :405-414
[7]   Renal cell carcinoma: Management of advanced disease [J].
Figlin, RA .
JOURNAL OF UROLOGY, 1999, 161 (02) :381-386
[8]   MHC class I antigens, immune surveillance, and tumor immune escape [J].
Garcia-Lora, A ;
Algarra, I ;
Garrido, F .
JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 195 (03) :346-355
[9]   MHC antigens and tumor escape from immune surveillance [J].
Garrido, F ;
Algarra, I .
ADVANCES IN CANCER RESEARCH, VOL 83, 2001, 83 :117-158
[10]   Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].
Garrido, F ;
RuizCabello, F ;
Cabrera, T ;
PerezVillar, JJ ;
LopezBotet, M ;
DugganKeen, M ;
Stern, PL .
IMMUNOLOGY TODAY, 1997, 18 (02) :89-95